Laurus Labs
Laurus Labs Limited, commonly referred to as Laurus Labs, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Founded in 2005, the company has established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs), generic formulations, and contract research services. With a strong focus on high-quality production, Laurus Labs offers a diverse portfolio that includes antiretroviral, oncology, and cardiovascular products, setting itself apart through its commitment to innovation and regulatory compliance. The company has achieved significant milestones, including multiple approvals from global regulatory authorities, which solidify its market position. Recognised for its robust research and development capabilities, Laurus Labs continues to expand its operational footprint across various regions, contributing to its reputation as a trusted partner in the pharmaceutical sector.
DitchCarbon Score
How does Laurus Labs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laurus Labs's score of 35 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Laurus Labs's reported carbon emissions
In 2023, Laurus Labs reported total carbon emissions of approximately 198,782,000 kg CO2e for Scope 1, 159,094,000 kg CO2e for Scope 2, and 73,322,000 kg CO2e for Scope 3 emissions. This reflects a commitment to transparency in their emissions reporting, covering all three scopes of greenhouse gas emissions. In 2022, the company recorded total emissions of about 360,398,000 kg CO2e, with Scope 1 emissions at 135,804,000 kg CO2e, Scope 2 at 163,134,000 kg CO2e, and Scope 3 at 65,014,000 kg CO2e. This indicates a significant focus on managing and reducing their carbon footprint. Laurus Labs has set near-term reduction targets, demonstrating their commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. However, they have not yet committed to a net-zero target. The company continues to work on initiatives aimed at reducing their greenhouse gas emissions and improving energy efficiency, as evidenced by their reported emission intensities. Overall, Laurus Labs is actively engaged in addressing climate change through their emissions reporting and reduction commitments, positioning themselves as a responsible player in the industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 68,321,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 248,303,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laurus Labs is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
